87 results on '"Hoschler, Katja"'
Search Results
2. End of 2022/23 Season Influenza Vaccine Effectiveness in Primary Care in Great Britain
3. Interim 2023/24 season influenza vaccine effectiveness in primary and secondary care in the United Kingdom
4. Robust and sensitive amplicon-based whole-genome sequencing assay of respiratory syncytial virus subtype A and B
5. Optimizing mood prior to influenza vaccination in older adults: A three-arm randomized controlled trial.
6. Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine
7. High attack rate in a large care home outbreak of SARS-CoV-2 BA.2.86, East of England, August 2023
8. Paediatric acute hepatitis of unknown aetiology: a national investigation and adenoviraemia case-control study in the UK
9. Post-pandemic development of sentinel surveillance of respiratory disease, in the context of the WHO mosaic framework: protocol for the English primary care network 2023-2024 (Preprint)
10. Postpandemic Sentinel Surveillance of Respiratory Diseases in the Context of the World Health Organization Mosaic Framework: Protocol for a Development and Evaluation Study Involving the English Primary Care Network 2023-2024 (Preprint)
11. Antibody Persistence After Primary SARS-CoV-2 Infection and Protection Against Future Variants Including Omicron in Adolescents: National, Prospective Cohort Study
12. An external quality assessment feasibility study; cross laboratory comparison of haemagglutination inhibition assay and microneutralization assay performance for seasonal influenza serology testing: A FLUCOP study
13. ADCC: An underappreciated correlate of cross-protection against influenza?
14. Genomic Investigations of Acute Hepatitis of Unknown Aetiology in Children
15. Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2
16. Validation of a Harmonized Enzyme-Linked-Lectin-Assay (ELLA-NI) Based Neuraminidase Inhibition Assay Standard Operating Procedure (SOP) for Quantification of N1 Influenza Antibodies and the Use of a Calibrator to Improve the Reproducibility of the ELLA-NI With Reverse Genetics Viral and Recombinant Neuraminidase Antigens: A FLUCOP Collaborative Study
17. SARS Antibody Testing in Children: Development of Oral Fluid Assays for IgG Measurements
18. Antibody Persistence after Primary Sars-Cov-2 Infection and Protection Against Future Variants Including Omicron in Adolescents: National, Prospective Cohort Study
19. Neutralising antibody activity against SARS-CoV-2 variants, including Omicron, in an elderly cohort vaccinated with BNT162b2
20. Antibody persistence and neutralising activity in primary school students and staff: Prospective active surveillance, June to December 2020, England
21. Seasonal trivalent inactivated influenza vaccine with topical imiquimod in immunocompromised patients: A randomized controlled trial
22. Assay Harmonization and Use of Biological Standards To Improve the Reproducibility of the Hemagglutination Inhibition Assay: a FLUCOP Collaborative Study
23. Antibody persistence and neutralising activity in primary school students and staff: prospective active surveillance, June to December 2020, England
24. SARS-CoV-2 IgG detection in human oral fluids
25. Seroprevalence of SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social Measures, London, UK
26. Seroprevalence of SARS-CoV-2 antibodies in university students: Cross-sectional study, December 2020, England
27. Author Correction: Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
28. Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021
29. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
30. Correlates of Protection Against Influenza
31. Antibodies to SARS-CoV-2 protect against re-infection during outbreaks in care homes, September and October 2020
32. Robust Antibody Responses in 70-80 Year Olds following 1 or 2 Doses of Pfizer COVID-19 Vaccine
33. Seroprevalence of SARS-CoV-2 Antibodies in University Students: Cross-sectional Study, December 2020, England
34. Inactivated pandemic 2009 H1N1 influenza A virus human vaccines have different efficacy after homologous challenge in the ferret model
35. Estimation of Seasonal Influenza Attack Rates and Antibody Dynamics in Children Using Cross-Sectional Serological Data
36. Forecasting the 2017/2018 seasonal influenza epidemic in England using multiple dynamic transmission models: a case study
37. Use of traditional serological methods and oral fluids to assess immunogenicity in children aged 2–16 years after successive annual vaccinations with LAIV
38. Forecasting the 2017/2018 seasonal influenza epidemic in England using multiple dynamic transmission models: a Case Study
39. Forecasting the 2017/2018 seasonal influenza epidemic in England using multiple dynamic transmission models: a Case Study
40. Cell-Mediated Immune Responses After Influenza Vaccination of Solid Organ Transplant Recipients: Secondary Outcomes Analyses of a Randomized Controlled Trial
41. Humoral response to natural influenza infection in solid organ transplant recipients
42. End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18
43. Serological surveillance of influenza in an English sentinel network: pilot study protocol
44. A Haemophilus sp. dominates the microbiota of sputum from UK adults with non-severe community acquired pneumonia and chronic lung disease
45. A comparison of viral microneutralization and haemagglutination inhibition assays as measures of seasonal inactivated influenza vaccine immunogenicity in the first year after reduced intensity conditioning, lymphocyte depleted allogeneic haematopoietic stem cell transplant
46. 1663. Marked Improvement in Pandemic H1N1 Component Shedding and Immunogenicity in 2017–2018 Russian-Backbone Live Attenuated Influenza Vaccine (LAIV) in Gambian Children
47. A Double-Blind, Randomized Trial of High-Dose vs Standard-Dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients
48. Comparison of mucosal lining fluid sampling methods and influenza-specific IgA detection assays for use in human studies of influenza immunity
49. A Randomized Trial of High-dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients
50. Humoral, T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.